Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The TLR7/8/9 antagonist IMO-8503 inhibits cancer-induced cachexia.

Croce CM, Calore F, Londhe P, Fadda P, Nigita G, Casadei L, Marceca GP, Fassan M, Lovat F, Gasparini P, Rizzotto L, Zanesi N, Jackson D, Mehta S, Nana-Sinkam P, Sampath D, Pollock RE, Guttridge DC.

Cancer Res. 2018 Sep 12. pii: canres.3878.2017. doi: 10.1158/0008-5472.CAN-17-3878. [Epub ahead of print]

PMID:
30209066
2.

NF-κB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model.

Peterson JM, Wang DJ, Shettigar V, Roof SR, Canan BD, Bakkar N, Shintaku J, Gu JM, Little SC, Ratnam NM, Londhe P, Lu L, Gaw CE, Petrosino JM, Liyanarachchi S, Wang H, Janssen PML, Davis JP, Ziolo MT, Sharma SM, Guttridge DC.

Nat Commun. 2018 Aug 24;9(1):3431. doi: 10.1038/s41467-018-05910-1.

3.

Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia.

Damrauer JS, Stadler ME, Acharyya S, Baldwin AS, Couch ME, Guttridge DC.

Eur J Transl Myol. 2018 Jun 6;28(2):7590. doi: 10.4081/ejtm.2018.7590. eCollection 2018 Apr 24.

4.

miR-133a function in the pathogenesis of dedifferentiated liposarcoma.

Yu PY, Lopez G, Braggio D, Koller D, Bill KLJ, Prudner BC, Zewdu A, Chen JL, Iwenofu OH, Lev D, Strohecker AM, Fenger JM, Pollock RE, Guttridge DC.

Cancer Cell Int. 2018 Jun 26;18:89. doi: 10.1186/s12935-018-0583-2. eCollection 2018.

5.

Classical NF-κB Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2.

Londhe P, Yu PY, Ijiri Y, Ladner KJ, Fenger JM, London C, Houghton PJ, Guttridge DC.

Front Oncol. 2018 Apr 11;8:104. doi: 10.3389/fonc.2018.00104. eCollection 2018.

6.

SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways.

Chen S, Bonifati S, Qin Z, St Gelais C, Kodigepalli KM, Barrett BS, Kim SH, Antonucci JM, Ladner KJ, Buzovetsky O, Knecht KM, Xiong Y, Yount JS, Guttridge DC, Santiago ML, Wu L.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3798-E3807. doi: 10.1073/pnas.1801213115. Epub 2018 Apr 2.

PMID:
29610295
7.

Cancer-associated cachexia.

Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH.

Nat Rev Dis Primers. 2018 Jan 18;4:17105. doi: 10.1038/nrdp.2017.105. Review.

PMID:
29345251
8.

Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.

Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC.

J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):358-368. doi: 10.1002/jcsm.12251. Epub 2018 Jan 7.

9.

Dysregulated Myogenesis in Rhabdomyosarcoma.

Yu PY, Guttridge DC.

Curr Top Dev Biol. 2018;126:285-297. doi: 10.1016/bs.ctdb.2017.10.007. Epub 2017 Oct 31.

PMID:
29305002
10.

Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions.

Nemer L, Krishna SG, Shah ZK, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Guttridge DC, Hinton A, Manilchuk A, Pawlik TM, Schmidt CR, Talbert EE, Bekaii-Saab T, Hart PA.

Pancreas. 2017 Oct;46(9):1152-1157. doi: 10.1097/MPA.0000000000000898.

PMID:
28902785
11.

NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development.

Ratnam NM, Peterson JM, Talbert EE, Ladner KJ, Rajasekera PV, Schmidt CR, Dillhoff ME, Swanson BJ, Haverick E, Kladney RD, Williams TM, Leone GW, Wang DJ, Guttridge DC.

J Clin Invest. 2017 Oct 2;127(10):3796-3809. doi: 10.1172/JCI91561. Epub 2017 Sep 11.

12.

NFκB signaling in alveolar rhabdomyosarcoma.

Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, Rubin BP, Guttridge DC, Keller C.

Dis Model Mech. 2017 Sep 1;10(9):1109-1115. doi: 10.1242/dmm.030882.

13.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.

PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.

14.

Additive amelioration of ALS by co-targeting independent pathogenic mechanisms.

Frakes AE, Braun L, Ferraiuolo L, Guttridge DC, Kaspar BK.

Ann Clin Transl Neurol. 2017 Jan 11;4(2):76-86. doi: 10.1002/acn3.375. eCollection 2017 Feb.

15.

Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization.

Qian Z, Rhodes CA, McCroskey LC, Wen J, Appiah-Kubi G, Wang DJ, Guttridge DC, Pei D.

Angew Chem Int Ed Engl. 2017 Feb 1;56(6):1525-1529. doi: 10.1002/anie.201610888. Epub 2016 Dec 30.

16.

Ken Fearon.

Skipworth RJ, Stephens NA, Johns N, Guttridge DC, Tisdale MJ, Baracos VE, Glass DJ.

Cell Metab. 2016 Dec 13;24(6):765-766. doi: 10.1016/j.cmet.2016.11.010. Epub 2016 Dec 13. No abstract available.

17.

Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB.

Mol Cancer Ther. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3.

18.

MyoD Regulates Skeletal Muscle Oxidative Metabolism Cooperatively with Alternative NF-κB.

Shintaku J, Peterson JM, Talbert EE, Gu JM, Ladner KJ, Williams DR, Mousavi K, Wang R, Sartorelli V, Guttridge DC.

Cell Rep. 2016 Oct 4;17(2):514-526. doi: 10.1016/j.celrep.2016.09.010.

19.

Analysis of Aerobic Respiration in Intact Skeletal Muscle Tissue by Microplate-Based Respirometry.

Shintaku J, Guttridge DC.

Methods Mol Biol. 2016;1460:337-43. doi: 10.1007/978-1-4939-3810-0_23.

PMID:
27492183
20.

ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma.

Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H.

Oncotarget. 2016 Jul 26;7(30):48533-48546. doi: 10.18632/oncotarget.10406.

21.

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld AK.

Cancer Discov. 2016 Sep;6(9):1036-51. doi: 10.1158/2159-8290.CD-16-0023. Epub 2016 Jun 27.

22.

Mechano-signalling pathways in an experimental intensive critical illness myopathy model.

Corpeno Kalamgi R, Salah H, Gastaldello S, Martinez-Redondo V, Ruas JL, Fury W, Bai Y, Gromada J, Sartori R, Guttridge DC, Sandri M, Larsson L.

J Physiol. 2016 Aug 1;594(15):4371-88. doi: 10.1113/JP271973. Epub 2016 Apr 24.

23.

Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-κB Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic Function.

Cardenas H, Arango D, Nicholas C, Duarte S, Nuovo GJ, He W, Voss OH, Gonzalez-Mejia ME, Guttridge DC, Grotewold E, Doseff AI.

Int J Mol Sci. 2016 Mar 1;17(3):323. doi: 10.3390/ijms17030323.

24.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ.

Mol Cancer Ther. 2016 May;15(5):1018-28. doi: 10.1158/1535-7163.MCT-15-0567. Epub 2016 Feb 23.

25.

A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Yu PY, Balkhi MY, Ladner KJ, Alder H, Yu L, Mo X, Kraybill WG, Guttridge DC, Iwenofu OH.

Lab Invest. 2016 Apr;96(4):481-91. doi: 10.1038/labinvest.2015.168. Epub 2016 Feb 15.

26.

An NF-κB--EphrinA5-Dependent Communication between NG2(+) Interstitial Cells and Myoblasts Promotes Muscle Growth in Neonates.

Gu JM, Wang DJ, Peterson JM, Shintaku J, Liyanarachchi S, Coppola V, Frakes AE, Kaspar BK, Cornelison DD, Guttridge DC.

Dev Cell. 2016 Jan 25;36(2):215-24. doi: 10.1016/j.devcel.2015.12.018. Epub 2016 Jan 14.

27.

A TGF-β pathway associated with cancer cachexia.

Guttridge DC.

Nat Med. 2015 Nov;21(11):1248-9. doi: 10.1038/nm.3988. No abstract available.

28.

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS.

J Natl Cancer Inst. 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. Print 2015 Dec.

PMID:
26464423
29.

Inflammation induced loss of skeletal muscle.

Londhe P, Guttridge DC.

Bone. 2015 Nov;80:131-142. doi: 10.1016/j.bone.2015.03.015. Review.

30.

Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Talbert EE, Guttridge DC.

Semin Cell Dev Biol. 2016 Jun;54:82-91. doi: 10.1016/j.semcdb.2015.09.009. Epub 2015 Sep 16. Review.

31.

Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.

Chadwick JA, Hauck JS, Lowe J, Shaw JJ, Guttridge DC, Gomez-Sanchez CE, Gomez-Sanchez EP, Rafael-Fortney JA.

FASEB J. 2015 Nov;29(11):4544-54. doi: 10.1096/fj.15-276782. Epub 2015 Jul 15.

32.

Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients.

Stephens NA, Skipworth RJ, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, Fearon KC.

J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):53-61. doi: 10.1002/jcsm.12005. Epub 2015 Mar 31.

33.

Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C.

Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.

34.

NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells.

Wang DJ, Ratnam NM, Byrd JC, Guttridge DC.

Cell Rep. 2014 Oct 9;9(1):90-103. doi: 10.1016/j.celrep.2014.08.049. Epub 2014 Sep 25.

35.

Inflammation based regulation of cancer cachexia.

Onesti JK, Guttridge DC.

Biomed Res Int. 2014;2014:168407. doi: 10.1155/2014/168407. Epub 2014 May 4. Review.

36.

Modeling human cancer cachexia in colon 26 tumor-bearing adult mice.

Talbert EE, Metzger GA, He WA, Guttridge DC.

J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):321-8. doi: 10.1007/s13539-014-0141-2. Epub 2014 Mar 26.

37.

Metabolomic profiling reveals severe skeletal muscle group-specific perturbations of metabolism in aged FBN rats.

Garvey SM, Dugle JE, Kennedy AD, McDunn JE, Kline W, Guo L, Guttridge DC, Pereira SL, Edens NK.

Biogerontology. 2014 Jun;15(3):217-32. doi: 10.1007/s10522-014-9492-5. Epub 2014 Mar 21.

38.

Cancer cachexia update in head and neck cancer: Pathophysiology and treatment.

Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Chang EY, Gourin CG, Der-Torossian H.

Head Neck. 2015 Jul;37(7):1057-72. doi: 10.1002/hed.23696. Epub 2015 Apr 7. Review.

PMID:
24634283
39.

Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7.

He WA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4525-9. doi: 10.1073/pnas.1402714111. Epub 2014 Mar 10.

40.

Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis.

Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, Popovich PG, Guttridge DC, Kaspar BK.

Neuron. 2014 Mar 5;81(5):1009-1023. doi: 10.1016/j.neuron.2014.01.013.

41.

Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.

Hemminger JA, Toland AE, Scharschmidt TJ, Mayerson JL, Guttridge DC, Iwenofu OH.

Mod Pathol. 2014 Sep;27(9):1238-45. doi: 10.1038/modpathol.2013.244. Epub 2014 Jan 24.

42.

Cancer cachexia update in head and neck cancer: Definitions and diagnostic features.

Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H.

Head Neck. 2015 Apr;37(4):594-604. doi: 10.1002/hed.23599. Epub 2014 Mar 25. Review.

PMID:
24415363
43.

NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy.

Kornegay JN, Peterson JM, Bogan DJ, Kline W, Bogan JR, Dow JL, Fan Z, Wang J, Ahn M, Zhu H, Styner M, Guttridge DC.

Skelet Muscle. 2014 Oct 23;4:18. doi: 10.1186/2044-5040-4-18. eCollection 2014.

44.

NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia.

He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, Wang J, Bloomston M, Muscarella P, Nau P, Shah N, Butchbach ME, Ladner K, Adamo S, Rudnicki MA, Keller C, Coletti D, Montanaro F, Guttridge DC.

J Clin Invest. 2013 Nov;123(11):4821-35.

45.

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC.

Sci Signal. 2013 Jul 30;6(286):ra63. doi: 10.1126/scisignal.2004177. Erratum in: Sci Signal. 2013 Sep 10;6(292):er6. Balkhi, Mumtaz Y [corrected to Balkhi, M Y].

46.

Mechanisms of impaired differentiation in rhabdomyosarcoma.

Keller C, Guttridge DC.

FEBS J. 2013 Sep;280(17):4323-34. doi: 10.1111/febs.12421. Epub 2013 Jul 31. Review.

47.

Regulation of skeletal muscle oxidative phenotype by classical NF-κB signalling.

Remels AH, Gosker HR, Bakker J, Guttridge DC, Schols AM, Langen RC.

Biochim Biophys Acta. 2013 Aug;1832(8):1313-25. doi: 10.1016/j.bbadis.2013.03.018. Epub 2013 Apr 3.

48.

Reining in nuclear factor-kappaB in skeletal muscle disorders.

Shintaku J, Guttridge DC.

Curr Opin Clin Nutr Metab Care. 2013 May;16(3):251-7. doi: 10.1097/MCO.0b013e3283600e79. Review.

PMID:
23493016
49.

Mechanisms for maintaining muscle.

Banerjee A, Guttridge DC.

Curr Opin Support Palliat Care. 2012 Dec;6(4):451-6. doi: 10.1097/SPC.0b013e328359b681. Review.

PMID:
23108340
50.

The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.

Hemminger JA, Ewart Toland A, Scharschmidt TJ, Mayerson JL, Kraybill WG, Guttridge DC, Iwenofu OH.

Mod Pathol. 2013 Feb;26(2):282-8. doi: 10.1038/modpathol.2012.133. Epub 2012 Aug 31.

Supplemental Content

Loading ...
Support Center